Trials / Completed
CompletedNCT05130112
Impact of Airways Function After HFNC Evaluated by IOS
Impact of Airways Function After Short-term Use of High-flow Nasal Cannula Gas Therapy Evaluated by Impulse Oscillometry Systems in Stable Chronic Obstructive Pulmonary Disease Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Fu Jen Catholic University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In addition to pharmacological treatment, nonpharmacological treatment with high-flow nasal cannula (HFNC) may play a vital role in the treatment of patients with chronic obstructive pulmonary disease (COPD). The impulse oscillation system (IOS) is new noninvasive technique to measure the impedance of different portions of the airway with higher sensitivity than that of the conventional pulmonary function test (PFT). However, whether IOS is an appropriate technique to evaluate the efficacy of HFNC in improving the impedance of peripheral small airways in patients with COPD is unclear.
Detailed description
Participants with stable COPD from the chest medicine outpatient department will be randomized into two groups receiving HFNC or nasal cannula (NC) for 10 min followed by a 4-week washout period and crossover alternatively. We used a novel analytical measurement technique, IOS, to detect the difference in airway impedance in the participants after the HFNC or NC interventions. All data, namely IOS parameters, transcutaneous partial pressure of carbon dioxide, peripheral oxygen saturation, body temperature, respiratory rate, pulse rate, blood pressure, and PFT results at the time of pre-HFNC, post-HFNC, pre-NC, and post-NC, were analysed using SPSS (version 25.0, IBM, Armonk, NY, USA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | high flow nasal cannula and nasal cannula | HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min.. NC is administered for 10 min. |
Timeline
- Start date
- 2019-12-13
- Primary completion
- 2020-03-31
- Completion
- 2020-09-09
- First posted
- 2021-11-22
- Last updated
- 2021-11-22
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05130112. Inclusion in this directory is not an endorsement.